Jinghua Zhang1, Liang Zhao2, Peisheng Lv1, Guizhi Liu1, Weiguo Du1, Fan Yang1, Youyou Du1, Luosha Zhao1. 1. Department of Cardiology, The Cardiology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China. 2. Department of Orthopaedics Orthopedics, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China.
Abstract
OBJECTIVE: To study the relationship between human platelet alloantigens-2 (HPA-2) polymorphism, Kozak sequence polymorphism, macroglycopeptide region variable number of tandem repeats (VNTR) polymorphism of GPIbα and coronary heart disease (CHD). METHODS: In the present study, blood obtained from 403 patients with CHD and 500 healthy controls was detected by PCR or PCR-RFLP methods to analyze the genotypes of HPA-2, Kozak sequence and VNTR. RESULTS: About HPA-2 polymorphism, there were significant differences between CHD group and control group in TM+MM genotype (13.15% vs. 8.60%, P<0.05; OR 1.609; 95% CI 1.051 to 2.463) and M alleles distributions (6.58% vs. 4.40%, P<0.05; OR 1.645; 95% CI 1.090 to 2.482). For Kozak sequence polymorphism, between control group and CHD group, the difference of CC genotype distribution is statistic significance (3.20% vs. 7.69%, P<0.05; OR 2.000; 95% CI 1.076 to 3.718). The genotype analysis of VNTR in Han People of Henan (AC, BC, BD, CC, CD and DD) proved that no association between any genotypes or alleles and CHD. There weren't any significant differences about haplotypes of these genes between control group and CHD group (P>0.05). CONCLUSIONS: The M allele of HPA-2 could be an important risk factor for CHD; the CC genotype of Kozak sequence would be a biomarker of genetic susceptibility about CHD; and each genotype of VNTR is no associated with CHD. No significant differences between control group and CHD group about haplotypes of these genes.
OBJECTIVE: To study the relationship between human platelet alloantigens-2 (HPA-2) polymorphism, Kozak sequence polymorphism, macroglycopeptide region variable number of tandem repeats (VNTR) polymorphism of GPIbα and coronary heart disease (CHD). METHODS: In the present study, blood obtained from 403 patients with CHD and 500 healthy controls was detected by PCR or PCR-RFLP methods to analyze the genotypes of HPA-2, Kozak sequence and VNTR. RESULTS: About HPA-2 polymorphism, there were significant differences between CHD group and control group in TM+MM genotype (13.15% vs. 8.60%, P<0.05; OR 1.609; 95% CI 1.051 to 2.463) and M alleles distributions (6.58% vs. 4.40%, P<0.05; OR 1.645; 95% CI 1.090 to 2.482). For Kozak sequence polymorphism, between control group and CHD group, the difference of CC genotype distribution is statistic significance (3.20% vs. 7.69%, P<0.05; OR 2.000; 95% CI 1.076 to 3.718). The genotype analysis of VNTR in Han People of Henan (AC, BC, BD, CC, CD and DD) proved that no association between any genotypes or alleles and CHD. There weren't any significant differences about haplotypes of these genes between control group and CHD group (P>0.05). CONCLUSIONS: The M allele of HPA-2 could be an important risk factor for CHD; the CC genotype of Kozak sequence would be a biomarker of genetic susceptibility about CHD; and each genotype of VNTR is no associated with CHD. No significant differences between control group and CHD group about haplotypes of these genes.
Authors: H-X Wang; C Leineweber; R Kirkeeide; B Svane; K Schenck-Gustafsson; T Theorell; K Orth-Gomér Journal: J Intern Med Date: 2007-03 Impact factor: 8.989
Authors: Vahid Afshar-Kharghan; Nevenka Matijevic-Aleksic; Chul Ahn; Eric Boerwinkle; Kenneth K Wu; José A López Journal: Blood Date: 2003-10-30 Impact factor: 22.113
Authors: Margareth C Ozelo; Andrea F Origa; Francisco J P Aranha; Antonio P Mansur; Joyce M Annichino-Bizzacchi; Fernando F Costa; Eleanor S Pollak; Valder R Arruda Journal: Thromb Haemost Date: 2004-08 Impact factor: 5.249